Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Bellevue Healthcare ETF

Key industry with high relevance (10% ofglobal GDP) and measurable innovationpower

Active management by a highly experienced team of specialists

Flexible trading on SIX Swiss Exchange (CHF and USD) and Deutsche Börse Xetra (EUR)

Indexed performance (as at: 23.10.2026)

NAV: USD 12.27 (27.10.2026)


01 Jan 2010 - 01 Jan 2010
An error occurred - no data to display
Bellevue Healthcare ETF
MSCI World Healthcare

Rolling performance (23.10.2026)

Bellevue Healthcare ETFMSCI World Healthcare
27.10.2025 - 27.10.202615.45%18.04%

Annualized performance (23.10.2026)

Bellevue Healthcare ETFMSCI World Healthcare
1 year15.45%18.04%
Since Inception p.a.20.12%22.48%

Cumulative performance (23.10.2026)

Bellevue Healthcare ETFMSCI World Healthcare
1M4.50%5.12%
YTD9.87%12.04%
1 year15.45%18.04%
Since Inception22.68%25.37%

Investment Focus

The investment objective of the Fund is to provide long-term capital growth from an actively managed portfolio comprising listed equity and equity-related securities of companies in the healthcare sector. The healthcare sector includes companies from the pharmaceutical, medical technology, biotechnology and related healthcare industries. The Fund promotes ESG characteristics as part of its implementation of the aforementioned investment policies.Show moreShow less

The Fund’s investment objective is to generate attractive and competitive long-term capital growth. It is particularly suited to investors with an investment horizon of at least 5 years. The Fund is exposed to the risks typical of equity investments.

General Information

Investment ManagerBellevue Asset Management AG
CustodianNorthern Trust
Fund AdministratorNorthern Trust
Launch date15.09.2025
Year end closing31. Mar
Management Fee0.55%
ISIN numberIE000R6TN604
BloombergCARE SW
WKNA41CY1

Legal Information

Legal formIrish Collective Asset-management Vehicle
SFDR categoryArticle 8

Key data (30.09.2026, base currency USD)

Beta0.98
Volatility14.35
Tracking error1.14
Active share17.15
Correlation1.00
Sharpe ratio0.89
Information ratio-1.28
Jensen's alpha-1.43
No. of positions69

Top 10 positions

Eli Lilly
Johnson & Johnson
AbbVie
UnitedHealth Group
ROCHE HLDG.
Merck & Co
Thermo Fisher
Amgen
AstraZeneca
Novartis
9.8%
6.9%
5.2%
5.2%
4.8%
4.7%
3.7%
3.5%
3.4%
3.2%

Market capitalization

5 - 15 bn
15 - 20 bn
> 20 bn
1.0%
1.5%
94.8%

Geographic breakdown

United States
Switzerland
Japan
Great Britain
France
Australia
Denmark
Germany
Netherlands
Sweden
New Zealand
Cash
72.2%
9.8%
5.4%
4.1%
1.6%
1.1%
1.0%
0.9%
0.8%
0.6%
0.4%
2.0%

Breakdown by sector

Pharma
Medtech
Services
Biotechnology
Life Sciences Tools
Generics/Spec.Pharma
Healthcare Technology
Other
Cash
46.5%
15.5%
14.1%
13.6%
5.5%
2.1%
0.5%
0.3%
2.0%

Currency

USD
CHF
JPY
GBP
EUR
AUD
ILS
DKK
SEK
NZD
CASH
71.2%
9.8%
5.4%
4.1%
3.4%
1.1%
1.0%
1.0%
0.6%
0.4%
2.0%

Benefits

  • Participate in the attractive growth dynamics of the global healthcare sector.
  • Access to a structurally relevant sector with a proven track record of innovation.
  • Unlock additional return potential through active management driven by conviction-based investment decisions.
  • Benefit from the advantages of an ETF (exchange-traded, cost-efficient, transparent).
  • Bellevue Asset Management - your specialist for healthcare investments since 1993.

Risks

  • The fund invests in equities. Equities are subject to price fluctuations and so are also exposed to the risk of price losses.
  • As an actively managed ETF, the fund's performance may deviate from the reference benchmark.
  • The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
  • The fund may invest a proportion of its assets in financial instruments that might under certain circumstances have a relatively low level of liquidity, which can in turn affect the fund’s liquidity.
  • The fund may engage in derivatives transactions. The increased opportunities gained come with an increased risk of losses.
Loading...

Show moreShow less

  • Lead Portfolio Manager

    Marcel Fritsch

    Marcel Fritsch has been with Bellevue Asset Management since 2008. He is head of healthcare funds & mandates and co-lead portfolio manager of the Bellevue Medtech & Services, Bellevue Digital Health and Bellevue AI Health funds. Prior to that, he worked as a consultant at Deloitte Touche Tohmatsu for over 3 years. His tasks in this function included analysis of business strategies, assessment of organizational structures and the valuation of companies in the run-up to corporate transactions. Marcel Fritsch holds a degree in business administration from the University of St. Gallen (HSG).
  • Senior Equity Analyst

    Annie Zeng

    Dr Annie Zeng joined Bellevue Asset Management in 2023 as a Healthcare equity analyst. Previously, she spent 2 years as pharma analyst at Bernstein in London covering EU and HK stocks. She also spent 1.5 years at Canaccord-Results as Healthcare investment banking analyst. Annie Zeng holds a PhD degree in Pharmacology from the University of Cambridge.
  • Senior Equity Analyst

    Guy Bettschart

    Guy Bettschart joined Bellevue Asset Management in 2025 as a Senior Equity Analyst. Previously, he spent two years as a buy-side healthcare analyst at Kieger AG and worked for Julius Baer in Zurich as a member of its equity research Team. Bettschart holds a BA in Banking & Finance from the University of Zurich and an MSc in Finance from the University of Lausanne and is a CFA Charterholder.
1

These insights might interest you